Joanne Wuensch
Stock Analyst at Citigroup
(4.52)
# 298
Out of 4,732 analysts
379
Total ratings
65.48%
Success rate
14.01%
Average return
Main Sectors:
Stocks Rated by Joanne Wuensch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Buy | $57 → $50 | $35.15 | +42.25% | 13 | Dec 11, 2024 | |
| SYK Stryker | Maintains: Buy | $411 → $450 | $383.42 | +17.36% | 12 | Dec 11, 2024 | |
| SGHT Sight Sciences | Maintains: Neutral | $5.8 → $4.6 | $2.83 | +62.54% | 9 | Dec 11, 2024 | |
| PEN Penumbra | Maintains: Neutral | $200 → $245 | $263.69 | -7.09% | 24 | Dec 11, 2024 | |
| NVRO Nevro | Maintains: Neutral | $6 → $5 | $4.57 | +9.41% | 19 | Dec 11, 2024 | |
| JNJ Johnson & Johnson | Maintains: Buy | $185 → $175 | $147.03 | +19.02% | 12 | Dec 11, 2024 | |
| ISRG Intuitive Surgical | Maintains: Buy | $567 → $640 | $592.64 | +7.99% | 15 | Dec 11, 2024 | |
| ITGR Integer Holdings | Maintains: Neutral | $130 → $145 | $141.00 | +2.84% | 4 | Dec 11, 2024 | |
| PODD Insulet | Maintains: Buy | $283 → $310 | $275.81 | +12.40% | 13 | Dec 11, 2024 | |
| EW Edwards Lifesciences | Maintains: Buy | $81 → $83 | $69.78 | +18.95% | 19 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $84.38 | +7.85% | 12 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $37 → $35 | $30.98 | +12.98% | 20 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $107 | $98.66 | +8.45% | 33 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $7.5 | $6.26 | +19.81% | 10 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $22 | $17.36 | +26.73% | 4 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $132 → $162 | $156.39 | +3.59% | 20 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $116 → $115 | $93.27 | +23.30% | 19 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $22 | $24.10 | -8.71% | 14 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $92 | $88.08 | +4.45% | 18 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $34.56 | +44.68% | 6 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $110 | $108.33 | +1.54% | 17 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $85 | $73.49 | +15.66% | 7 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $134 → $120 | $109.56 | +9.53% | 22 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $88 → $103 | $84.74 | +21.55% | 2 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $126 → $128 | $113.48 | +12.80% | 19 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $220 → $250 | $237.38 | +5.32% | 5 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $67 → $69 | $84.37 | -18.22% | 5 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $109 → $127 | $239.78 | -47.03% | 6 | Dec 10, 2018 |
Tandem Diabetes Care
Dec 11, 2024
Maintains: Buy
Price Target: $57 → $50
Current: $35.15
Upside: +42.25%
Stryker
Dec 11, 2024
Maintains: Buy
Price Target: $411 → $450
Current: $383.42
Upside: +17.36%
Sight Sciences
Dec 11, 2024
Maintains: Neutral
Price Target: $5.8 → $4.6
Current: $2.83
Upside: +62.54%
Penumbra
Dec 11, 2024
Maintains: Neutral
Price Target: $200 → $245
Current: $263.69
Upside: -7.09%
Nevro
Dec 11, 2024
Maintains: Neutral
Price Target: $6 → $5
Current: $4.57
Upside: +9.41%
Johnson & Johnson
Dec 11, 2024
Maintains: Buy
Price Target: $185 → $175
Current: $147.03
Upside: +19.02%
Intuitive Surgical
Dec 11, 2024
Maintains: Buy
Price Target: $567 → $640
Current: $592.64
Upside: +7.99%
Integer Holdings
Dec 11, 2024
Maintains: Neutral
Price Target: $130 → $145
Current: $141.00
Upside: +2.84%
Insulet
Dec 11, 2024
Maintains: Buy
Price Target: $283 → $310
Current: $275.81
Upside: +12.40%
Edwards Lifesciences
Dec 11, 2024
Maintains: Buy
Price Target: $81 → $83
Current: $69.78
Upside: +18.95%
Dec 11, 2024
Maintains: Buy
Price Target: $85 → $91
Current: $84.38
Upside: +7.85%
Dec 11, 2024
Maintains: Neutral
Price Target: $37 → $35
Current: $30.98
Upside: +12.98%
Dec 11, 2024
Maintains: Buy
Price Target: $98 → $107
Current: $98.66
Upside: +8.45%
Dec 11, 2024
Downgrades: Neutral
Price Target: $17 → $7.5
Current: $6.26
Upside: +19.81%
Dec 11, 2024
Downgrades: Neutral
Price Target: $24 → $22
Current: $17.36
Upside: +26.73%
Dec 11, 2024
Upgrades: Buy
Price Target: $132 → $162
Current: $156.39
Upside: +3.59%
Dec 6, 2024
Maintains: Buy
Price Target: $116 → $115
Current: $93.27
Upside: +23.30%
Nov 5, 2024
Maintains: Sell
Price Target: $16 → $22
Current: $24.10
Upside: -8.71%
Oct 1, 2024
Maintains: Neutral
Price Target: $85 → $92
Current: $88.08
Upside: +4.45%
Oct 1, 2024
Maintains: Neutral
Price Target: $45 → $50
Current: $34.56
Upside: +44.68%
Aug 22, 2024
Maintains: Buy
Price Target: $135 → $110
Current: $108.33
Upside: +1.54%
Aug 22, 2024
Maintains: Neutral
Price Target: $94 → $85
Current: $73.49
Upside: +15.66%
Jul 10, 2024
Maintains: Neutral
Price Target: $134 → $120
Current: $109.56
Upside: +9.53%
Apr 3, 2024
Maintains: Buy
Price Target: $88 → $103
Current: $84.74
Upside: +21.55%
Apr 3, 2024
Maintains: Buy
Price Target: $126 → $128
Current: $113.48
Upside: +12.80%
Dec 12, 2022
Upgrades: Neutral
Price Target: $220 → $250
Current: $237.38
Upside: +5.32%
Nov 17, 2022
Maintains: Neutral
Price Target: $67 → $69
Current: $84.37
Upside: -18.22%
Dec 10, 2018
Upgrades: Outperform
Price Target: $109 → $127
Current: $239.78
Upside: -47.03%